References
- Brooke MH, Fenichel GM, Griggs RC et al. Clinical investigation in Duchenne dystrophy: 2. Determination of the ‘power’ of therapeutic trials based on the natural history. Muscle Nerve 1983; 6: 91–103.
- Medical Research Council. Aids to the examination of the peripheral nervous system. London: Her Majesty’s Stationery Office, 1976:14.
- Andres PL, Finison LJ, Conlon T, Thibodeau LM, Munsat TL. Use of composite scores (megascores) to measure deficit in amyo- trophic lateral sclerosis. Neurology 1988; 38: 405–408.
- The National Isometric Muscle Strength (NIMS) Database Consortium. Muscular weakness assessment: use of normal isometric strength data. Arch Phys Med Rehabil 1996; 77: 1251–1255.
- Andres PL, Hedlund W, Finison L, Conlon T, Felmus M, Munsat TL. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 1986; 36: 937–941.
- Miller RG, Moore D, Young LA et al. Placebo controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Western Amyotrophic Lateral Sclerosis Study Group. 1996; 47:1383–1388.
- Miller RG, Moore DH II, Gelinas DF et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56: 843–848.
- Bradley WG, Anderson F, Bromberg M et al. ALS CARE Study Group. Current management of ALS: comparison of the ALS CARE database and the AAN Practice Parameter. The American Academy of Neurology. Neurology 2001; 57(3): 500–504.
- Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyo- trophic lateral sclerosis in Olmsted County, Minnesota, 1925–1998. Neurology 2002; 59(2): 280–282.
- Moss AN, Casey P, Stocking CB et al. Home ventilation for amyotrophic lateral sclerosis patients: outcomes, costs, and patient, family and physician attitudes. Neurology 1993; 43(2): 438–443.